Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915860 · ClinicalTrials.gov registry record · Phase 3
Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 47
- Enrollment target
NCT03915860 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 47 participants.
The verdict
NCT03915860, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 47 participants
- Enrollment target
Study Summary
Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris
Interventions
- DRUG Trifarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2019-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03915860
The ClinicalTrials.gov registry entry for NCT03915860 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trifarotene is the first listed.
NCT03915860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03915860 about?
NCT03915860 is a clinical study titled "Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris". Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris
What is the current status of trial NCT03915860?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 47 participants. The study started on 2019-03-27. Estimated completion is 2019-12-23.
What interventions are being tested in trial NCT03915860?
The interventions under investigation include: Trifarotene (DRUG).
Who is sponsoring clinical trial NCT03915860?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.